Hantz Financial Services Inc. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 22.5% during the 3rd quarter, Holdings Channel reports. The fund owned 11,305 shares of the company’s stock after purchasing an additional 2,074 shares during the period. Hantz Financial Services Inc.’s holdings in IDEXX Laboratories were worth $5,903,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after purchasing an additional 288,471 shares during the period. Dimensional Fund Advisors LP lifted its position in IDEXX Laboratories by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in IDEXX Laboratories by 97.3% during the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on IDXX shares. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They issued a “buy” rating on the stock. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. KeyCorp assumed coverage on IDEXX Laboratories in a report on Monday, October 12th. They issued a “sector weight” rating for the company. Barclays decreased their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, Citigroup upped their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.
Check Out Our Latest Stock Report on IDXX
Insider Buying and Selling
In other news, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the sale, the executive vice president directly owned 7,169 shares of the company’s stock, valued at $4,936,501.71. This represents a 55.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total value of $17,678,196.60. Following the sale, the insider owned 83,803 shares in the company, valued at $58,929,431.57. This trade represents a 23.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,428 shares of company stock valued at $28,567,934 in the last ninety days. Company insiders own 0.79% of the company’s stock.
IDEXX Laboratories Price Performance
NASDAQ:IDXX opened at $700.65 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.88. The firm has a market cap of $55.20 billion, a price-to-earnings ratio of 47.25 and a beta of 1.55. The company has a 50 day moving average price of $565.71 and a 200-day moving average price of $573.58. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the firm posted $3.22 earnings per share. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.
IDEXX Laboratories Profile
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
